Meeting
2022 ASCO Annual Meeting
Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation–positive locally advanced or metastatic non–small cell lung cancer (NSCLC).
Authors
Fan Zhang
Department of Oncology, Chinese PLA General Hospital, Beijing, China
Fan Zhang , Yi Hu , Xiao Han , ZhiSong Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
ChiCTR2100047453
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9151)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9151
Abstract #
TPS9151
Poster Bd #
130a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
First Author: Fengying Wu
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.
First Author: Yuankai Shi
Poster
2023 ASCO Annual Meeting
VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).
First Author: Alexander I. Spira